Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

Last updated:
2026-07-25
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE 3 RANDOMIZED, OPEN-LABEL STUDY OF MK-5684 VERSUS ALTERNATIVE ABIRATERONE ACETATE OR ENZALUTAMIDE IN PARTICIPANTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PREVIOUSLY TREATED WITH NEXT-GENERATION HORMONAL AGENT (NHA) AND TAXANE-BASED CHEMOTHERAPY

Intervention/treatment:
OPEVESOSTAT (MK-5684)
Medical condition:
PROSTATE CANCER METASTATIC CASTRATION RESISTANT
Protocol code:
MK-5684-003
Control number:
280447
Status:
Recruiting
Approved:
November 28, 2023
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT06136624
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Toll Free Number
Role
CONTACT
Phone:
1-888-577-8839
Sponsor
MERCK CANADA INC

Locations

Alberta

Cross Cancer Institute ( Site 0332)
Edmonton, Alberta, T6G 1Z2
Recruiting
Name
Study Coordinator
Role
CONTACT
Phone:
7804328762

Ontario

Princess Margaret Cancer Centre ( Site 0330)
Toronto, Ontario, M5G 2M9
Recruiting
Name
Study Coordinator
Role
CONTACT
Phone:
(416) 946-4501
Sunnybrook Research Institute ( Site 0331)
Toronto, Ontario, M4N 3M5
Recruiting
Name
Study Coordinator
Role
CONTACT
Phone:
647-533-1023
The Ottawa Hospital - General Campus-The Ottawa Hospital Cancer Centre ( Site 0336)
Ottawa, Ontario, K1H 8L6
Recruiting
Name
Study Coordinator
Role
CONTACT
Phone:
613-737-7700

Quebec

Centre Hospitalier de l'Université de Montréal ( Site 0326)
Montreal, Quebec, H2X 3E4
Active, not recruiting
Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0327)
Québec, Quebec, G1J 1Z4
Recruiting
Name
Study Coordinator
Role
CONTACT
Phone:
418 525-4444
Centre Intégré de Santé et de Services Sociaux de la Montérégie-Centre ( Site 0328)
Greenfield Park, Quebec, J4V 2H1
Recruiting
Name
Study Coordinator
Role
CONTACT
Phone:
4504665000 ext 3226
Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Univer ( Site 0329)
Sherbrooke, Quebec, J1H 5H4
Active, not recruiting
Did you find what you were looking for?